- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Depression Research and Treatment
Volume 2012 (2012), Article ID 752563, 8 pages
Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses
1Department of Environmental Health Science, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan
2Department of Food Science and Nutrition, Nara Women's University, Nara 630-8506, Japan
Received 3 August 2012; Revised 9 November 2012; Accepted 21 November 2012
Academic Editor: Michael Maes
Copyright © 2012 Yasuko Kitagishi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- G. Thornicroft and M. Tansella, “The balanced care model for global mental health,” Psychological Medicine, pp. 1–15, 2012.
- S. E. Hammack, M. A. Cooper, and K. R. Lezak, “Overlapping neurobiology of learned helplessness and conditioned defeat: implications for PTSD and mood disorders,” Neuropharmacology, vol. 62, no. 2, pp. 565–575, 2012.
- A.-M. Bao, H. G. Ruhé, S.-F. Gao, and D. F. Swaab, “Neurotransmitters and neuropeptides in depression,” Handbook of Clinical Neurology, vol. 106, pp. 107–136, 2012.
- M. Maes, M. Berk, L. Goehler et al., “Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways,” BMC Medicine, vol. 10, p. 66, 2012.
- A. R. Cole, “GSK3 as a sensor determining cell fate in the brain,” Frontiers in Molecular Neuroscience. In press.
- J.-M. Beaulieu, “A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health,” Journal of Psychiatry and Neuroscience, vol. 37, no. 1, pp. 7–16, 2012.
- L. Freland and J.-M. Beaulieu, “Inhibition of GSK3 by lithium, from single molecules to signaling networks,” Frontiers in Molecular Neuroscience, vol. 5, article 14, 2012.
- F. Benedetti, I. Bollettini, I. Barberi, et al., “Lithium and GSK3-β Promoter gene variants influence white matter microstructure in bipolar disorder,” Neuropsychopharmacology. In press.
- T. Del'guidice and J. M. Beaulieu, “Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo,” Molecular Pharmacology, vol. 73, no. 5, pp. 1339–1342, 2008.
- R. L. Hauger, J. A. Olivares-Reyes, F. M. Dautzenberg, J. B. Lohr, S. Braun, and R. H. Oakley, “Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy,” Neuropharmacology, vol. 62, no. 2, pp. 705–714, 2012.
- R. K. Farooq, E. Isingrini, A. Tanti, et al., “Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?” Behavioural Brain Research, vol. 231, no. 1, pp. 130–137, 2012.
- T. Weichhart and M. D. Säemann, “The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications,” Annals of the Rheumatic Diseases, vol. 67, supplement 3, pp. iii70–iii74, 2008.
- J. Y. Kim, X. Duan, C. Y. Liu et al., “DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212,” Neuron, vol. 63, no. 6, pp. 761–773, 2009.
- J.-M. Beaulieu, R. R. Gainetdinov, and M. G. Caron, “Akt/GSK3 signaling in the action of psychotropic drugs,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 327–347, 2009.
- Z. You, C. Luo, W. Zhang et al., “Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression,” Behavioural Brain Research, vol. 225, no. 1, pp. 135–141, 2011.
- A. Spooren, K. Kolmus, G. Laureys et al., “Interleukin-6, a mental cytokine,” Brain Research Reviews, vol. 67, no. 1-2, pp. 157–183, 2011.
- C. Song and H. Wang, “Cytokines mediated inflammation and decreased neurogenesis in animal models of depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 760–768, 2011.
- S. Moylan, M. Maes, N. R. Wray, and M. Berk, “The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications,” Molecular Psychiatry. In Press.
- L. Die, P. Yan, Z. J. Jiang, T. Min Hua, W. Cai, and L. Xing, “Glycogen synthase kinase-3 beta inhibitor suppresses Porphyromonas gingivalis lipopolysaccharide-induced CD40 expression by inhibiting nuclear factor-kappa B activation in mouse osteoblasts,” Molecular Immunology, vol. 52, no. 1, pp. 38–49, 2012.
- M. Haidinger, M. Poglitsch, R. Geyeregger et al., “A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation,” Journal of Immunology, vol. 185, no. 7, pp. 3919–3931, 2010.
- B. Leonard and M. Maes, “Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression,” Neuroscience and Biobehavioral Reviews, vol. 36, no. 2, pp. 764–785, 2012.
- L. Sghendo and J. Mifsud, “Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model,” Journal of Pharmacy and Pharmacology, vol. 64, no. 3, pp. 317–325, 2012.
- D. J. David, J. Wang, B. A. Samuels et al., “Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders,” Neuroscientist, vol. 16, no. 5, pp. 578–591, 2010.
- W. Young, “Review of lithium effects on brain and blood,” Cell Transplantation, vol. 18, no. 9, pp. 951–975, 2009.
- D. Muyllaert, A. Kremer, T. Jaworski et al., “Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?” Genes, Brain and Behavior, vol. 7, supplement 1, pp. 57–66, 2008.
- A. Jazwa and A. Cuadrado, “Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases,” Current drug targets, vol. 11, no. 12, pp. 1517–1531, 2010.
- N. K. Idriss, A. D. Blann, and G. Y. H. Lip, “Hemoxygenase-1 in cardiovascular disease,” Journal of the American College of Cardiology, vol. 52, no. 12, pp. 971–978, 2008.
- J. Hammond and J.-L. Balligand, “Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 2, pp. 330–340, 2012.
- A. E. Courtney and A. P. Maxwell, “Heme Oxygenase 1: does It have a role in renal cytoprotection?” The American Journal of Kidney Diseases, vol. 51, no. 4, pp. 678–690, 2008.
- R. Hardeland, “Melatonin: signaling mechanisms of a pleiotropic agent,” BioFactors, vol. 35, no. 2, pp. 183–192, 2009.
- K. Sheppard, K. M. Kinross, B. Solomon, R. B. Pearson, and W. A. Phillips, “Targeting PI3 kinase/AKT/mTOR signaling in cancer,” Critical Reviews in Oncogenesis, vol. 17, no. 1, pp. 69–95, 2012.
- E. Aksamitiene, A. Kiyatkin, and B. N. Kholodenko, “Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance,” Biochemical Society Transactions, vol. 40, no. 1, pp. 139–146, 2012.
- N. Okumura, H. Yoshida, Y. Kitagishi, and S. Matsuda, “PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis,” Advances in Hematology, vol. 2012, Article ID 843085, 6 pages, 2012.
- C. Gao, C. Hlscher, Y. Liu, and L. Li, “GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease,” Reviews in the Neurosciences, vol. 23, no. 1, pp. 1–11, 2012.
- M. S. Song, L. Salmena, and P. P. Pandolfi, “The functions and regulation of the PTEN tumour suppressor,” Nature Reviews Molecular Cell Biology, vol. 13, no. 5, pp. 283–296, 2012.
- R. A. Nemenoff, P. A. Simpson, S. B. Furgeson et al., “Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1α,” Circulation Research, vol. 102, no. 9, pp. 1036–1045, 2008.
- N. Okumura, H. Yoshida, Y. Nishimura, Y. Kitagishi, and S. Matsuda, “Terpinolene, a component of herbal sage, downregulates AKT1 expression in K562 cells,” Oncology Letters, vol. 3, no. 2, pp. 321–324, 2012.
- M. G. Pezzolesi, P. Platzer, K. A. Waite, and C. Eng, “Differential expression of PTEN-Targeting microRNAs miR-19a and miR-21 in cowden syndrome,” The American Journal of Human Genetics, vol. 82, no. 5, pp. 1141–1149, 2008.
- A. Zamani and Z. Qu, “Serotonin activates angiogenic phosphorylation signaling in human endothelial cells,” FEBS Letters, vol. 586, no. 16, pp. 2360–2365, 2012.
- M. Iwabayashi, Y. Taniyama, F. Sanada et al., “Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice,” Atherosclerosis, vol. 220, no. 2, pp. 337–342, 2012.
- A. Ahluwalia and A. S. Tarnawski, “Critical role of hypoxia sensor- HIF-1α in VEGF gene activation: implications for angiogenesis and tissue injury healing,” Current Medicinal Chemistry, vol. 19, no. 1, pp. 90–97, 2012.
- J. Chen, P. R. Somanath, O. Razorenova et al., “Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo,” Nature Medicine, vol. 11, no. 11, pp. 1188–1196, 2005.
- F. Shi, T.-Z. Zhao, S. Zhang et al., “Effects of simulated microgravity on human umbilical vein endothelial cell angiogenesis and role of the PI3K-Akt-eNOS signal pathway,” PLoS ONE, vol. 7, no. 7, Article ID 40365, 2012.
- C. K. Kim, S. B. Lee, T. L. X. Nguyen et al., “Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization,” Experimental Cell Research, vol. 318, no. 2, pp. 136–143, 2012.
- Q. Xu, L.-Z. Liu, X. Qian et al., “MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis,” Nucleic Acids Research, vol. 40, no. 2, pp. 761–774, 2012.
- J. E. Lee, J. S. Kang, Y.-W. Ki, S.-H. Lee, S.-J. Lee, and H. C. Koh, “Akt/GSK3β signaling is involved in fipronil-induced apoptotic cell death of human neuroblastoma SH-SY5Y cells,” Toxicology Letters, vol. 202, no. 2, pp. 133–141, 2011.
- E. S. Emamian, “AKT/GSK3 signaling pathway and schizophrenia,” Frontiers in Molecular Neuroscience, vol. 5, article 33, pp. 1–12, 2012.
- S. I. Yun, H. Y. Yoon, and Y. S. Chung, “Glycogen synthase kinase-3β regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells,” Apoptosis, vol. 14, no. 6, pp. 771–777, 2009.
- N. M. Enman and E. M. Unterwald, “Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse,” Behavioural Brain Research, vol. 231, no. 1, pp. 217–225, 2012.
- W. T. O'Brien and P. S. Klein, “Validating GSK3 as an in vivo target of lithium action,” Biochemical Society Transactions, vol. 37, no. 5, pp. 1133–1138, 2009.
- T. Dal-Cim, S. Molz, J. Egea et al., “Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3β pathway,” Neurochemistry International, vol. 61, no. 3, pp. 397–404, 2012.
- L. Mo, C. Yang, M. Gu et al., “PI3K/Akt signaling pathway-induced heme oxygenase-1 upregulation mediates the adaptive cytoprotection of hydrogen peroxide preconditioning against oxidative injury in PC12 cells,” International Journal of Molecular Medicine, vol. 30, no. 2, pp. 314–320, 2012.
- N. L. Neubauer, E. C. Ward, P. Patel et al., “Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis,” Hormones and Cancer, vol. 2, no. 3, pp. 170–181, 2011.
- H. Zhou, Y. Luo, and S. Huang, “Updates of mTOR inhibitors,” Anti-Cancer Agents in Medicinal Chemistry, vol. 10, no. 7, pp. 571–581, 2010.
- J. J. Gibbons, R. T. Abraham, and K. Yu, “Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth,” Seminars in Oncology, vol. 36, supplement 3, pp. S3–S17, 2009.
- E. B. Larson and F. S. Zollman, “The effect of sleep medications on cognitive recovery from traumatic brain injury,” Journal of Head Trauma Rehabilitation, vol. 25, no. 1, pp. 61–67, 2010.
- O. V. Forlenza, V. J. de Paula, R. MacHado-Vieira, B. S. Diniz, and W. F. Gattaz, “Does lithium prevent Alzheimers disease?” Drugs and Aging, vol. 29, no. 5, pp. 335–342, 2012.
- G. Chen, L. D. Huang, W. Z. Zeng, and H. K. Manji, “Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability,” International Journal of Neuropsychopharmacology, vol. 4, no. 1, pp. 47–64, 2001.
- M. Maes, B. E. Leonard, A. M. Myint, M. Kubera, and R. Verkerk, “The new “5-HT” hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 702–721, 2011.